Dexcom, Inc., a global leader in glucose biosensing, has released its new "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. This comprehensive report, building upon initial multi-region findings from Europe and the Middle East (EMEA), provides crucial insights into the perceptions of diabetes technology from over 400 healthcare professionals (HCPs) and individuals with Type 2 diabetes throughout the U.S.

A significant finding from the U.S. report indicates that a majority of surveyed HCPs believe continuous glucose monitoring (CGM) holds greater potential to impact the future of Type 2 diabetes care than advancements in diabetes medications. This sentiment is echoed by the fact that more than half (59%) of U.S. HCPs consider better access to CGM as the most effective way to help people with Type 2 diabetes manage their condition over the next decade.

The report also highlights strong support for CGM becoming a standard of care. A remarkable 96% of providers surveyed in the U.S. agree that CGM should be the standard of care for individuals using multiple daily insulin injections, and 94% concur that it should be the standard of care for those on basal insulin. Furthermore, there is unanimous support among U.S. HCPs, with 100% recommending CGM in combination with GLP-1 or SGLT2 medications, citing superior expected patient outcomes. This aligns with 79% of providers in EMEA who also supported this combination.

Improving access and understanding of CGM is crucial, and HCPs believe this can be achieved through additional coverage and educational support for Americans with Type 2 diabetes, as well as more training for healthcare providers. Specifically, 60% of U.S. HCPs stated that increased funding or budget to cover CGM could significantly boost its usage among people with Type 2 diabetes.

Jake Leach, president and chief operating officer of Dexcom, reinforced the company's commitment, stating, “The findings of our State of Type 2 Report in the U.S. reaffirm what we’ve always believed to be true: CGM is central to the future of Type 2 diabetes care. To help drive the greatest impact for patients, a continued focus on diabetes education and access to CGMs is needed – and Dexcom is committed to advancing these around the world.”

During the ADA conference, Dexcom will present extensive clinical data showcasing the benefits of CGM for those living with Type 2 diabetes, alongside new outcomes from early Stelo users. Grammy-nominated singer, actor, and producer Lance Bass, a Dexcom Warrior, will share his first-hand experience of saying “Bye” to fingersticks* after being diagnosed with Latent Autoimmune Diabetes in Adults (LADA), also known as Type 1.5 diabetes. He will join experts to discuss how early CGM adoption improves diabetes management through personalized care, and innovations in Dexcom technology, including new features and in-app reports.

Dexcom's clinical data presentations at the conference further support the technology's benefits across various insulin therapies for people with Type 2 diabetes. These studies contribute to an extensive body of evidence, showing benefits ranging from reduced mortality risk among insulin-using individuals to decreased diabetes-related distress and improved self-management among non-insulin using individuals. A real-world observational study specifically highlighted how Dexcom G7 use in non-insulin using Type 2 diabetes patients was associated with significantly reduced diabetes-related distress and enhanced adherence to healthy eating plans and exercise routines, underscoring CGM as a powerful tool for behavior modification.

Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for over 25 years, empowering individuals to take control of their health through innovative biosensing technology and transforming how people manage diabetes and track their glucose. (*Fingersticks are required for diabetes treatment decisions if symptoms or expectations do not match readings.)